This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Zacks.com featured highlights include Caterpillar, Applied Materials, Toll Brothers, Walmart and Dr. Reddy's Laboratories
by Zacks Equity Research
Caterpillar, Applied Materials, Toll Brothers, Walmart and Dr. Reddy's Laboratories are part of the Zacks Screen of the Week article.
Zacks.com featured highlights include Trip.com, Dr. Reddy's Laboratories, J&J Snack Foods and Granite Ridge Resources
by Zacks Equity Research
Trip.com, Dr. Reddy's Laboratories, J&J Snack Foods and Granite Ridge Resources are part of the Zacks Screen of the Week article.
5 Dividend Growth Stocks to Buy in a Weak Market
by Sweta Killa
Caterpillar (CAT), Applied Materials (AMAT), Toll Brothers (TOL), Walmart (WMT) and Dr. Reddy's (RDY) could be solid choices for investors amid market weakness.
Buy These 4 Low-Beta Stocks to Sail Through the Choppy Market
by Nilanjan Banerjee
It is imperative to build a portfolio of low-beta stocks to sail through a volatile market. Trip.com (TCOM), Dr. Reddy's (RDY), J&J Snack (JJSF) and Granite Ridge (GRNT) are poised to gain.
TEVA to Pay $225 Million to Settle Price-Fixing Charges (Revised)
by Zacks Equity Research
TEVA agrees to pay a fine of $225 million over five years per a DPA. Out of this amount, $22.5 million will be due each year from 2024 through 2027 and $135 million will become due in 2028.
TEVA to Pay $250 Million to Settle Price-Fixing Charges
by Zacks Equity Research
TEVA agrees to pay a fine of $225 million over five years per a DPA. Out of this amount, $22.5 million will be due each year from 2024 through 2027 and $135 million will become due in 2028.
Here's Why You Should Add Dr. Reddy's (RDY) to Your Portfolio
by Zacks Equity Research
Dr. Reddy's (RDY) continues to enjoy a strong foothold in the global generics market due to its deep generic drugs pipeline. The company is also looking to strengthen its biosimilars portfolio.
5 Growth Opportunities Thriving on Relative Price Strength
by Nilanjan Choudhury
HURN, EHC, RDY, BOOM and HWKN are five stocks with explosive relative price strength.
Add These 4 Top-Performing Liquid Stocks for Strong Returns
by Vaishali Doshi
Here are four top-ranked liquid stocks, Dr. Reddy's (RDY), Surmodics (SRDX), Fluor Corporation (FLR) and GigaCloud Technology (GCT), which investors can add to their portfolio for solid gains.
Zacks Industry Outlook Highlights Amphastar Pharmaceuticals, Dr. Reddy's Laboratories and Teva Pharmaceutical
by Zacks Equity Research
Amphastar Pharmaceuticals, Dr. Reddy's Laboratories and Teva Pharmaceutical are part of the Zacks Industry Outlook article.
3 Generic Drug Stocks to Watch Amid Improving Market Prospects
by Sundeep Ganoria
The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry is gradually improving. New product launches provide some respite to AMPH, RDY and TEVA.
Zacks.com featured highlights Caterpillar, Walmart, KB Home, Progress Software and Dr. Reddy's
by Zacks Equity Research
Caterpillar, Walmart, KB Home, Progress Software and Dr. Reddy's have been highlighted in this Screen of The Week article.
Dr. Reddy's Laboratories Ltd (RDY) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Doctor Reddy's (RDY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
5 Dividend Growth Stocks for Safe and Stable Returns
by Sweta Killa
Caterpillar (CAT), Walmart (WMT), KB Home (KBH), Progress Software (PRGS) and Dr. Reddy's (RDY) could be solid choices for your portfolio.
Zacks.com featured highlights Trip.com, Dr. Reddy's, Sterling Check and MINISO Group
by Zacks Equity Research
Trip.com, Dr. Reddy's, Sterling Check and MINISO Group have been highlighted in this Screen of The Week article.
Buy These 4 Low-Beta Stocks to Counter the Choppy Market
by Nilanjan Banerjee
It is imperative to build a portfolio of low-beta stocks to sail through a volatile market. Trip.com (TCOM), Dr. Reddy's (RDY), Sterling Check (STER) and MINISO Group (MNSO) are poised to gain.
TEVA Q2 Earnings & Sales Top as Austedo Outperforms, Stock Up
by Zacks Equity Research
TEVA's second-quarter results were strong as it beat estimates for earnings as well sales.
Dr. Reddy's (RDY) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Dr. Reddy's (RDY) reports better-than-expected fiscal first-quarter 2024 results.
Journey Medical (DERM) to Post Skin Disease Data, Stock Rises 26%
by Zacks Equity Research
Journey Medical (DERM) rises 26% on Monday after announcing the tentative date for reporting top-line results from its late-stage studies evaluating DFD-29 in treating papulopustular rosacea.
Journey Medical (DERM) Up on Rosacea Candidate's Positive Data
by Zacks Equity Research
Journey Medical's (DERM) phase I study, assessing the impact of DFD-29 on the microbial flora of healthy adults, obtains its primary endpoints.
Dr. Reddy's (RDY) Meets Goals in Actemra Biosimilar Study
by Zacks Equity Research
Dr. Reddy's (RDY) announces meeting primary and secondary endpoints in the phase I study of its proposed tocilizumab biosimilar for the treatment of rheumatoid arthritis in adults.
Zacks Industry Outlook Highlights Amphastar, Dr. Reddy's and Teva Pharmaceutical
by Zacks Equity Research
Amphastar, Dr. Reddy's and Teva Pharmaceutical have been highlighted in this Industry Outlook article.
3 Generic Drug Stocks to Watch Amid Macro Headwinds
by Sundeep Ganoria
The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to AMPH, RDY and TEVA.
ARS Pharma (SPRY) Gets FDA Panel Vote for Epinephrine Nasal Spray
by Zacks Equity Research
ARS Pharmaceuticals (SPRY) gains as it gets favorable votes from the FDA advisory committee for epinephrine spray to treat severe allergic reactions.
Dr. Reddy's (RDY) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Dr. Reddy's (RDY) reports better-than-expected fourth-quarter results where both earnings and revenues beat estimates.